Observational studyRespiratory research2019
The composition of the pulmonary microbiota in sarcoidosis - an observational study.
Observational study in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- The Impact of Nutritional Status on Survival and Development of Sarcoidosis: A Scoping Review of Current Evidence and Research Gaps.Nutrients · 2026Review
- Editorial: Unlocking the microbial code: potential role in sarcoidosis pathogenesis and treatment.Frontiers in immunology · 2026Article
- Gut microbiota and sarcoidosis: a concise review.Frontiers in medicine · 2026Review
- Whole genome sequencing of the pulmonary microbiome in interstitial lung disease subtypes.Respiratory research · 2025Article
- Microbiome Against the Background of the Complex Aetiology in Sarcoidosis-What Do We Already Know?Life (Basel, Switzerland) · 2025Review
- Overview of multi-omics approaches for pulmonary sarcoidosis.EC pulmonology and respiratory medicine · 2025Article
- Infectious and non-infectious precipitants of sarcoidosis.Journal of autoimmunity · 2024Review
- Lung Microbiome in Lung Cancer: A Systematic Review.Microorganisms · 2024Review
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- Visualization of the individual blood microbiome to study the etiology of sarcoidosis.Computational and structural biotechnology journal · 2023Article
- The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis.Microbiome · 2022Article
- The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease.FEBS open bio · 2022Article
- Epigenetics and sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Comparative analysis of the alveolar microbiome in COPD, ECOPD, Sarcoidosis, and ILD patients to identify respiratory illnesses specific microbial signatures.Scientific reports · 2021Article
- Molecular approach to the classification of chronic fibrosing lung disease-there and back again.Virchows Archiv : an international journal of pathology · 2021Review
- Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population-based nested case-control study.European journal of epidemiology · 2020Article
- Sarcoidosis: Causes, Diagnosis, Clinical Features, and Treatments.Journal of clinical medicine · 2020Review
- Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.Journal of biomedical science · 2019Review
- Trained Innate Immunity Not Always Amicable.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcoidosis is a systemic disease of unknown etiology. The disease mechanisms are largely speculative and may include the role microbial patterns that initiate and drive an underlying immune process. The aim of this study was to characterize the microbiota of the lung of patients with sarcoidosis and compare its composition and diversity with the results from patients with other interstitial lung disease (ILD) and historic healthy controls.
methodsPatients (sarcoidosis, n = 31; interstitial lung disease, n = 19) were recruited within the PULMOHOM study, a prospective cohort study to characterize inflammatory processes in pulmonary diseases. Bronchoscopy of the middle lobe or the lingula was performed and the recovered fluid was immediately sent for analysis of the pulmonary microbiota by 16sRNA gene sequencing. Subsequent bioinformatic analysis was performed to compare the groups.
resultsThere were no significant differences between patients with sarcoidosis or other ILDs with regard to microbiome composition and diversity. In addition, the abundance of the genera Atopobium, Fusobacterium, Mycobacterium or Propionibacterium were not different between the two groups. There were no gross differences to historical healthy controls.
conclusionThe analysis of the pulmonary microbiota based on 16sRNA gene sequencing did not show a significant dysbiosis in patients with sarcoidosis as compared to other ILD patients. These data do not exclude a microbiological component in the pathogenesis of sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.